Drug Safety Issues Will Raise Regulatory Expectations, Bristol Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol expects a more critical regulatory environment for its recently submitted muraglitazar NDA. Greater scrutiny by FDA could translate into more focused labeling, CEO Dolan says.